Hetrombopag olamine    (DrugBank: Hetrombopag)

2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
60再生不良性貧血2
63特発性血小板減少性紫斑病3

60. 再生不良性貧血 [臨床試験数:218,薬物数:362(DrugBank:81),標的遺伝子数:39,標的パスウェイ数:155
Searched query = "Aplastic anemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 218 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03825744
(ClinicalTrials.gov)
March 5, 201930/1/2019Hetrombopag or Placebo in Treatment-Naive Severe Aplastic AnemiaA Phase III Multicenter Randomized Study of Hetrombopag or Placebo in Treatment-Naive Severe Aplastic AnemiaSevere Aplastic AnemiaDrug: Hetrombopag Olamine+Standard Therapy;Drug: Placebo+Standard TherapyJiangsu HengRui Medicine Co., Ltd.NULLRecruiting15 Years75 YearsAll180Phase 3China
2NCT03557099
(ClinicalTrials.gov)
June 20, 20183/6/2018A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia (SAA) PatientA Multicentre, Open-label, Single-arm, Phase II Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Patients With Severe Aplastic AnemiaSevere Aplastic AnemiaDrug: Hetrombopag OlamineJiangsu HengRui Medicine Co., Ltd.NULLRecruiting18 YearsN/AAll55Phase 1;Phase 2China

63. 特発性血小板減少性紫斑病 [臨床試験数:311,薬物数:185(DrugBank:39),標的遺伝子数:43,標的パスウェイ数:132
Searched query = "Idiopathic thrombocytopenic purpura", "Primary immune thrombocytopenia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 311 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03222843
(ClinicalTrials.gov)
June 30, 201718/7/2017Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) PatientA Phase III,Multicentre, Randomized, Double-Blind and Open-Label Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Patients With Idiopathic Thrombocytopenic PurpuraIdiopathic Thrombocytopenic PurpuraDrug: Hetrombopag Olamine;Drug: matching placeboJiangsu HengRui Medicine Co., Ltd.NULLRecruiting18 YearsN/AAll414Phase 3China
2NCT02614846
(ClinicalTrials.gov)
August 201519/11/2015Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) PatientsA Safety, Pharmacokinetics and Pharmacodynamics Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic PurpuraChronic Idiopathic Thrombocytopenic PurpuraDrug: Hetrombopag OlamineJiangsu HengRui Medicine Co., Ltd.NULLRecruiting18 Years65 YearsBoth29Phase 1China
3NCT02403440
(ClinicalTrials.gov)
April 201420/3/2015A Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) PatientsA Safety, Pharmacokinetics and Pharmacodynamics Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic PurpuraPurpura, Thrombocytopenic, IdiopathicDrug: Hetrombopag OlamineJiangsu HengRui Medicine Co., Ltd.NULLRecruiting18 Years65 YearsBoth24Phase 1China